| Identification | Back Directory | [Name]
5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-[[L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- | [CAS]
1022094-34-3 | [Synonyms]
5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-[[L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- | [Molecular Formula]
C46H56N6O16 | [MOL File]
1022094-34-3.mol | [Molecular Weight]
948.97 |
| Chemical Properties | Back Directory | [Boiling point ]
1198.9±65.0 °C(Predicted) | [density ]
1.50±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
7.35±0.60(Predicted) | [color ]
Orange to red |
| Hazard Information | Back Directory | [Uses]
Val-Cit-PABC-DOX (compound 10109), an epsilon-poly-L-lysine-based drug conjugate, is an agent-linker conjugate for ADC by using a DNA topoisomerase I and topoisomerase II inhibitor, Doxorubicin (HY-15142), linked via the linker, Val-Cit-PABC[1]. | [IC 50]
Traditional Cytotoxic Agents | [References]
[1] Furao Zhang, et al. Epsilon-poly-l-lysine-based drug conjugate, intermediate thereof, and application thereof. WO2023078464A1. |
|
|